DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qrjx72/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Ascendis Pharma A/S
- AstraZeneca PLC
- Convergence Pharmaceuticals Ltd.
- D-Pharm Ltd.
- Delpor, Inc.
- Eli Lilly and Company
- Intas Pharmaceuticals Ltd.
- Intra-Cellular Therapies, Inc.
- KemPharm, Inc.
- MarcoPolo Pharmaceuticals SA
- Navigen Pharmaceuticals, Inc.
- Neurocrine Biosciences, Inc.
- Omeros Corporation
- Otsuka Holdings Co., Ltd.
- Pfizer Inc.
- Reviva Pharmaceuticals Inc.
- Richter Gedeon Nyrt.
- SK Biopharmaceuticals Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Limited
- Zogenix, Inc.
- Zysis Limited
Drug Profiles
- ACP-005
- aripiprazole
- aripiprazole CR
- BRDK-98958073
- cariprazine
- CNV-1061436
- DP-VPA
- Drug for Bipolar Disorder
- Drug for Cancer and Neurodegenerative Disease
- Endoxifen
- ITI-007
- KP-303
- lurasidone hydrochloride
- LY-2979165
- NP-202
- paliperidone palmitate
- PGW-5
- quetiapine fumarate ER
- ramelteon
- risperidone
- RP-5063
- SKL-PSY
- Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia
- Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders
- Small Molecule to Target GPR50 for CNS and Metabolic Disorders
- Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System
- Synthetic Peptides to Inhibit IMPase for Bipolar Disorder
- uridine triacetate
- ziprasidone hydrochloride
For more information visit http://www.researchandmarkets.com/research/qrjx72/bipolar_disorder
